BlackRock Investment Management’s Larimar Therapeutics LRMR Stock Holding History

BlackRock Investment Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$283K	Hold	7,428	–	–	﹤0.01%	3182
2016 Q3	$295K	Sell	7,428 -16	-0.2%	-$727	﹤0.01%	3183
2016 Q2	$535K	Buy	7,444 +2,543	+52%	+$201K	﹤0.01%	3031
2016 Q1	$393K	Buy	4,901 +79	+2%	+$6.24K	﹤0.01%	2982
2015 Q4	$364K	Sell	4,822 -1,052	-18%	-$169K	﹤0.01%	3110
2015 Q3	$2.25M	Sell	5,874 -51	-0.9%	-$23K	﹤0.01%	1993
2015 Q2	$2.46M	Buy	5,925 +2,908	+96%	+$1.22M	﹤0.01%	2062
2015 Q1	$1.43M	Buy	3,017 +1,365	+83%	+$648K	﹤0.01%	2271
2014 Q4	$611K	Buy	1,652 +71	+4%	+$18.3K	﹤0.01%	2891
2014 Q3	$373K	Buy	+1,581	New	+$358K	﹤0.01%	3115

Other funds holding LRMR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock Investment Management's LRMR Position: Q4 2016 in Review

BlackRock Investment Management held its Larimar Therapeutics (LRMR) position steady in Q4 2016 at 7,428 shares worth $283K. The position accounts for ﹤0.01% of the portfolio, ranked #3182.

BlackRock Investment Management first reported a position in LRMR in Q3 2014 and has held it in 10 quarters since. The position peaked at $2.46M in Q2 2015. 81 funds tracked by Wall St. Rank hold LRMR as of Q4 2016.

BlackRock Investment Management held 7,428 shares of Larimar Therapeutics worth $283K as of Q4 2016.
BlackRock Investment Management left its Larimar Therapeutics share count unchanged in Q4 2016.
Larimar Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3182 holding.
BlackRock Investment Management first reported a position in Larimar Therapeutics in Q3 2014 and has held it in 10 quarters since.
BlackRock Investment Management's Larimar Therapeutics position peaked at $2.46M in Q2 2015.
81 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.